CHANCE CHRISTENSEN: Open Payments
NPI 1841784535 · POCATELLO, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,787 in 89 payments from 16 companies in 2025. Trend: 2023 $1,175 · 2024 $1,660 · 2025 $1,787
Food & beverage: $1,632Education: $155
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $413 |
| Amgen Inc. | 21 | $297 |
| Tris Pharma Inc | 2 | $290 |
| Vanda Pharmaceuticals Inc. | 12 | $229 |
| Janssen Biotech, Inc. | 2 | $155 |
| Axsome Therapeutics, Inc. | 5 | $102 |
| UCB, Inc. | 2 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $45 |
| Corium, LLC | 4 | $40 |
| Phathom Pharmaceuticals, Inc. | 3 | $36 |
Products named: Dyanavel XR, QULIPTA, OTEZLA, FANAPT, TREMFYA, VRAYLAR, Auvelity, Bimzelx.
Industry payments across ID — which companies pay providers there.
